Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of TAS-102 plus ramucirumab in unresectable advanced or recurrent gastric cancer
jRCT2080224529Phase 2Completed
- Sponsor
- Taiho Pharmaceutical Co., Ltd.
- Start
- Jan 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of trifluridine + tipiracil and ramucirumab in gastric cancer (GC), sponsored by Taiho Pharmaceutical Co., Ltd. Started Jan 2019; status: completed.
02
Drugs
trifluridine + tipiracilramucirumab
03
Conditions
gastric cancer (GC)
Beyond the preview
Go deeper on jRCT2080224529.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080224529.